GD2 — Drug Target

All drugs that target GD2 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Glycolipid Disialoganglioside-directed Antibody [EPC] · Monoclonal antibody

Marketed (2)

• DANYELZA · Y-MABS THERAPEUTICS INC · Glycolipid Disialoganglioside-directed Antibody [EPC] · Neuroscience
  Naxitamab-gqgk binds to GD2 on neuroblastoma cells, inducing CDC and ADCC.
• Ch14.18 · United Therap · Glycolipid Disialoganglioside-directed Antibody [EPC] · Oncology
  Dinutuximab binds to GD2 on neuroblastoma cells and induces cell lysis via ADCC and CDC.

Phase 3 pipeline (2)

• monoclonal antibody Ch14.18 · National Cancer Institute (NCI) · Monoclonal antibody · Oncology
  Ch14.18 is a monoclonal antibody that targets GD2, a disialoganglioside found on the surface of certain cancer cells.
• monoclonal antibodies GD2 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Monoclonal antibody · Oncology
  GD2-targeting monoclonal antibodies work by binding to GD2, a glycolipid found on the surface of certain cancer cells, to induce cell death and inhibit tumor growth.

Phase 2 pipeline (1)

• Dinutuximab. Immunotherapy · Fundació Sant Joan de Déu · Monoclonal antibody · Oncology
  Monoclonal antibody targeting GD2